

Special Issue

Angiogenesis and Anti-angiogenesis in Health and Diseases

Message from the Guest Editor

Angiogenic switch is an important event during tumor progression where the balance between pro and antiangiogenic factors slope towards a proangiogenic outcome, leading to the transition from avascularized neoplasia to a vascularized tumor. Tumor vessels often appeared abnormal in shape and function, and they are more loosely connected with surrounding cells, influencing drug delivery. Therefore, preclinical and clinical studies have focused on the role of mural cells, stabilizing the tumor vasculature through various signaling pathways, which influence many hallmarks of cancer. However, both defective vasculature and excessive ECM generation and pericyte coverage represent a physical barrier for effective drug delivery, leading to the resistance to the anti-tumor therapies. Angiogenesis is also occurring under other pathological conditions, such as diabetic retinopathy, ischemic stroke and atherogenesis. Current efforts aim to advance research toward the discovery of new molecular targets, gene profiling, resistance mechanisms, and diagnostic and prognostic markers to overcome disease progression by improving the therapeutic options.

Guest Editor

Dr. Elmina Mammadova-Bach

Walther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilian-University, 80336 Munich, Germany

Deadline for manuscript submissions

closed (30 September 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/106609

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).